Tweet
Cornercap Investment Counsel Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,416 shares of the biopharmaceutical company's stock after acquiring an additional 12,979 shares during the quarter. Cornercap Investment Counsel Inc.'s holdings in Pfizer were worth $4,168,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of PFE. BlackRock Inc. increased its stake in Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company's stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares during the last quarter. Mackenzie Financial Corp grew its stake in shares of Pfizer by 29,164.7% in the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company's stock valued at $415,878,000 after buying an additional 11,442,753 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its stake in shares of Pfizer by 81.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company's stock valued at $691,583,000 after buying an additional 8,563,358 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 11.9% in the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company's stock valued at $2,562,162,000 after buying an additional 7,534,957 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Pfizer by 46.6% in the fourth quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company's stock valued at $816,395,000 after buying an additional 7,161,892 shares in the last quarter. 69.28% of the stock is owned by institutional investors. Get Pfizer alerts:
PFE has been the subject of a number of research reports. JPMorgan Chase & Co. reaffirmed a "$37.66" rating on shares of Pfizer in a research note on Wednesday, July 18th. Morgan Stanley reaffirmed a "buy" rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, June 11th. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the company a "buy" rating in a research note on Wednesday, June 13th. Morningstar set a $43.50 price objective on Pfizer and gave the company a "buy" rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research raised Pfizer from a "hold" rating to a "buy" rating and set a $41.00 price objective for the company in a research note on Tuesday, July 3rd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company's stock. The stock has an average rating of "Hold" and a consensus target price of $40.95. In related news, insider Alexander R. Mackenzie sold 25,642 shares of Pfizer stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $39.51, for a total value of $1,013,115.42. Following the completion of the transaction, the insider now directly owns 127,954 shares in the company, valued at $5,055,462.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company's stock, valued at $2,979,552. The disclosure for this sale can be found here . Over the last quarter, insiders sold 785,453 shares of company stock valued at $29,937,357. 0.06% of the stock is currently owned by company insiders.
NYSE:PFE opened at $41.42 on Friday. The firm has a market capitalization of $243.65 billion, a P/E ratio of 15.63, a P/E/G ratio of 1.98 and a beta of 0.96. Pfizer Inc. has a 12-month low of $32.32 and a 12-month high of $41.64. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.07. The firm had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. Pfizer's revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, August 3rd will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a yield of 3.28%. Pfizer's dividend payout ratio (DPR) is presently 51.32%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Trading Penny Stocks
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE). Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter 